Showing 3751-3760 of 5773 results for "".
- Lighthouse Guild Awards College Scholarships of $10,000 Each To 15 Students Who Are Blind or Visually Impairedhttps://modernod.com/news/lighthouse-guild-awards-college-scholarships-of-10000-each-to-15-students-who-are-blind-or-visually-impaired/2480919/Lighthouse Guild announced that it is awarding 15 college scholarships of $10,000 each to students from across the country who are visually impaired and will be entering college or graduate school in the Fall. Lighthouse Guild scholarships are based on strong academic accomplishment and
- Vision Expo West 2022 Opens Hotel Reservationshttps://modernod.com/news/vision-expo-west-2022-opens-hotel-reservations/2480917/The Vision Council and RX, co-organizers of Vision Expo, announced that reservations are now being accepted at Vision Expo West’s partner hotels for
- Johnson & Johnson Vision to Launch Acuvue Oasys Max 1-Day Contact Lenses in Several Marketshttps://modernod.com/news/johnson-johnson-vision-to-launch-acuvue-oasys-max-1-day-contact-lenses-in-several-markets/2480914/Johnson & Johnson Vision announced it has received FDA clearance, Health Canada approval, and completed CE Mark activities for its latest contact lens, Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day Multifocal. The announcement comes during the 125th Annual AOA Congress and 54th<
- New Study Shows Intraocular Lens Centration and Stability May Be Improved When Zepto Capsulotomy Platform is Used with Purkinje Reflectionshttps://modernod.com/news/new-study-shows-intraocular-lens-centration-and-stability-may-be-improved-when-zepto-capsulotomy-platform-is-used-with-purkinje-reflections/2480912/Centricity Vision announced the publication of a clinical study describing how to use Purkinje reflections at patient fixation for capsulotomy centration and 360-degree capsular overlap with the Zepto platform to help achieve improved visual outcomes. Published in the Journal
- Vyluma and Laboratoires Théa Enter into Licensing Agreement for Commercialization of Childhood Myopia Drughttps://modernod.com/news/vyluma-and-laboratoires-thea-enter-into-licensing-agreement-commercialization-of-childhood-myopia-drug/2480911/Vyluma and Laboratoires Théa announced that they have recently entered into an exclusive licensing agreement for the registration and commercialization of NVK002 in Canada, Mexico, and select South American Countries. This agreement represents an expansion of the previous
- Lensar Receives FDA Clearance of the ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/lensar-receives-fda-clearance-of-the-ally-adaptive-cataract-treatment-system/2480910/Lensar announced FDA 510(k) clearance for its ALLY Adaptive Cataract Treatment System. ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond-laser-assisted cataract surgery (FLACS) procedure in a single, sterile environment. "The (
- First-of-its-Kind Study Finds Artificial Intelligence Screenings Improve Eye Care Access in Sub-Saharan Africahttps://modernod.com/news/first-of-its-kind-study-finds-artificial-intelligence-screenings-improve-eye-care-access-in-sub-saharan-africa/2480906/Orbis announced new research findings demonstrating that diabetic retinopathy screenings supported by artificial intelligence (AI) enhanced patients’ speed and uptake of referral services in Rwanda, which can help reduce vision loss due to diabetes in the region. The study is
- Aurion Biotech Appoints Michael Goldstein, MD, as President and Chief Medical Officerhttps://modernod.com/news/aurion-biotech-appoints-dr-michael-goldstein-as-president-and-chief-medical-officer/2480904/Aurion Biotech announced it has appointed Michael Goldstein, MD, as president and chief medical officer. Dr. Goldstein will lead the company’s clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cel
- Nacuity Pharmaceuticals Strengthens Scientific Advisory Board with Appointment of Nancy Holekamp, MD, and Richard L. Lindstrom, MDhttps://modernod.com/news/nacuity-pharmaceuticals-strengthens-scientific-advisory-board-with-appointment-of-nancy-holekamp-md-and-richard-l-lindstrom-md/2480903/Nacuity Pharmaceuticals announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Nancy Holekamp, MD, and Richard L. Lindstrom, MD. “We are thrilled and grateful to welcome two world-renowned ophthalmologists who bring to our SAB significant and essent
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-tranquility2-trial-in-dry-eye-disease/2480902/Aldeyra Therapeutics announced the achievement of the primary endpoint in the phase 3 TRANQUILITY-2 clinical trial (TRANQUILITY-2) of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was statistically superior to vehicle for each of the two presp